Critical appraisal of stem cell therapy in peripheral arterial disease: Do current scientific breakthroughs offer true promise or false hope?

摘要: Over the last forty years in the field of peripheral arterial disease, there has been a plethora research into cell-based therapies for tissue repair, regeneration and angiogenesis, progressing from protein-based to gene stem cell research. Initial pre-clinical successes have given birth whole industry, aimed at translating these laboratory hopes clinical successes. However, heretofore these expected results failed materialize, part due the lack attention ischaemic desert like systemically diseased patient which cells are being implanted. Unsatisfactory clinical outcomes on treatment Critical Limb Ischaemia (CLI) forced researchers to direct their efforts less intimidating challenge claudication and to lower outcome thresholds from superior “non-inferior”. Major questions safety and durability also arisen. What needs be objectively established is the impact net health these therapies. Infusion or injection therapy still considered experimental investigational. In this review we examine evidence angiogenic therapies, focusing specifically trials, an attempt answer the question “Is experiment or will light at end tunnel?”